Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021
Research

Costs and Outcomes of Integrated Human African Trypanosomiasis Surveillance System Using Rapid Diagnostic Tests, Democratic Republic of the Congo

Rian SnijdersComments to Author , Alain Fukinsia, Yves Claeys, Epco Hasker, Alain Mpanya, Erick Miaka, Filip Meheus, and Marleen Boelaert1
Author affiliations: Swiss Tropical and Public Health Institute, Basel, Switzerland (R. Snijders); University of Basel, Basel (R. Snijders); Institute of Tropical Medicine, Antwerp, Belgium (R. Snijders, Y. Claeys, E. Hasker, M. Boelaert); Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo (A. Fukinsia, A. Mpanya, E. Miaka); International Agency for Research on Cancer, Lyon, France (F. Meheus)

Main Article

Figure 4

Sensitivity analysis on main cost drivers for HAT diagnosis and treatment, Democratic Republic of the Congo. HAT, human African trypanosomiasis.

Figure 4. Sensitivity analysis on main cost drivers for HAT diagnosis and treatment, Democratic Republic of the Congo. HAT, human African trypanosomiasis.

Main Article

1Deceased.

Page created: June 10, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external